Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.

International Urogynecology Journal
Linda CardozoAdrian S Wagg

Abstract

This study evaluated the efficacy and safety of flexible-dose fesoterodine and factors associated with dose escalation in subjects with overactive bladder (OAB). In this 12-week, open-label study, 331 adults with OAB symptoms for ≥3 months, ≥8 micturitions and ≥3 urgency episodes per 24 h and who reported at least "some moderate" bladder-related problems were treated with fesoterodine 4 mg once daily for 4 weeks, with the option to escalate to 8 mg for the remaining 8 weeks based on discussion of efficacy and tolerability with the investigator. Factors influencing dose escalation were identified using stepwise logistic regression. Efficacy was assessed via 3-day bladder diaries and patient-reported outcomes. Of the subjects, 59 % dose escalated at week 4; 93 % of escalators cited insufficient clinical response. The decision to escalate was most often made by the subject (alone or with the investigator). Improvements from baseline were observed in diary and patient-reported outcomes at weeks 4 and 12. Smaller improvements in micturition frequency and worse bladder-related problems at week 4 were significantly associated with increased likelihood of dose escalation; baseline micturition frequency, age, sex, body mass index, antim...Continue Reading

References

Jan 9, 1998·British Journal of Obstetrics and Gynaecology·C J KelleherS Salvatore
Sep 11, 2002·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·K CoyneP Abrams
Jun 12, 2003·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Pat Ray ReeseCon J Kelleher
Jul 1, 2004·Neurourology and Urodynamics·Kerry AveryPaul Abrams
Feb 12, 2005·BJU International·Linda CardozoEboo Versi
Dec 13, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Andreas M PleilCon J Kelleher
Jun 15, 2007·Neurourology and Urodynamics·Elisabeth PiaultPaul Abrams
Oct 17, 2007·The Journal of Urology·Victor W NittiTamara Bavendam
Mar 18, 2008·Urology·Vik KhullarZhonghong Guan
May 19, 2009·Current Opinion in Urology·Karl-Erik AnderssonAlan J Wein
Nov 17, 2009·BJU International·Joshua S BennerLinda Brubaker
Sep 24, 2010·BJU International·Jean-Jacques WyndaeleMyung-Soo Choo
Jan 22, 2011·Neurourology and Urodynamics·Karin S CoyneChristopher R Chapple

❮ Previous
Next ❯

Citations

Dec 4, 2012·International Journal of General Medicine·Jean-Jacques Wyndaele
Jul 24, 2012·Current Urology Reports·Philip E V Van Kerrebroeck
Jun 6, 2014·International Journal of Clinical Practice·S A KaplanUNKNOWN Assessment of Fesoterodine after Tolterodine ER (AFTER) Study Group
Apr 24, 2014·International Journal of Clinical Practice·J J WyndaeleD Arumi
Aug 27, 2016·Neurourology and Urodynamics·Angie RantellVik Khullar
Mar 31, 2018·International Urogynecology Journal·Howard B GoldmanFady Ntanios
May 8, 2019·Journal of General Internal Medicine·Ethan M BalkPeter C Jeppson
Feb 20, 2020·Lower Urinary Tract Symptoms·Li-Chen Chen, Hann-Chorng Kuo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.